Kawasaki disease: Clinical spectrum of 88 patients in a high-prevalence African-American population

Journal of the National Medical Association

Volumn 100, Issue 1, 2008, Pages 28-34

  Marquez, Javier ^a   Gedalia, Osnat ^a,d   Candia, Liliana ^a   Ranjit, Kylathu ^a   Hescock, George C ^a   Espinoza, Luis R ^a,b   Stopa, Aluizio R ^a,c   Gedalia, Abraham ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Section of Rheumatology

^c Division of Pediatric Cardiology

^d Division of Pediatric Rheumatology

Author keywords

African Americans; Brain; Children adolescents; Heart; Immunoglobulin; Inflammation; Kawasaki disease; Vascular

Indexed keywords

ACETYLSALICYLIC ACID; HEMOGLOBIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE;

ADOLESCENT; AFRICAN AMERICAN; ANALYTIC METHOD; ARTICLE; CAUCASIAN; CHILD; CLINICAL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY ANEURYSM; FEMALE; FOLLOW UP; HUMAN; INFANT; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; RISK FACTOR;

EID: 38949193228     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0027-9684(15)31171-8     Document Type: Article

References (26)

1. Dajani AS, Taubert KA, Gerber MA, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation. 1993;87:1776-1780.
2. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes. Jpn J Allergy. 1967;16:178-222.
3. Kawasaki T, Kosaki F, Okawa S, et al. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54:271-276.
4. Kushner HI, Turner CL, Bastian JF, et al. The narratives of Kawasaki disease. Bull Hist Med. 2004;78(2):410-439.
5. Gedalia A. Kawasaki disease: an update. Curr Rheum Rep. 2002;4:25-29.
6. Abuhammour WM, Hasan RA, Eljamal A, et al. Kawasaki disease hospitalizations in a predominantly African-American population. Clin Pediatr. 2005;44(8) 721-725.
7. Porcalla AR, Sable CA, Patel KM, et al. The epidemiology of Kawasaki disease in an urban hospital: does African American race protect against coronary artery aneurysms? Pediatr Cardiol. 2005; 26(6):775-781.
8. Suzuki H, Noda E, Miyawaki M, et al. Pediatr Intern. 2001;43:115-119.
9. Nasr I, Tomentzki AJP, Scholfied OMV. Kawasaki disease: an update. Clin Exper Dermatol. 2001;26:6-12.
10. Han RH, Sinclair B, Newman A, et al. Recognition and management of Kawasaki disease. CMAJ. 2000;162(6):807-812.
11. Centers for Disease Control. Multiple outbreaks of Kawasaki syndrome - United States. MMWR. 1985;34:33-35.
12. Newberger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114:1708-1733.
13. Yanagawa H, Nakamura Y, Ojima T, et al. Changes in epidemic patterns of Kawasaki disease in Japan. Pediatr Infect Dis J. 1999;18:64-66.
14. Rowley AH, Shulman ST. Kawasaki syndrome. Pediatr Clin North Am. 1999;46(2):313-329.
15. Tsuda E, Kamiya T, Ono Y, et al. Incidence of Stenotic Lesions Predicted by Acute Phase Changes in Coronary Arterial Diameter During Kawasaki Disease. Pediatr Cardiol. 05/12/2004.
16. Yanagawa H, Nakamura Y, Yashiro M. Results of the nation wide epidemiologic survey of Kawasaki disease in 1999 and 2000 in Japan. J Pediatr Pract. 2002;65:332-342.
17. Mori M, Imagawa T, Yasui K, et al. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr. 2000;137:177-180.
18. Nakamura Y, Yashiro M, Uehara R, et al. Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int.2004;46(1):33-38.
19. Yalcindag A, Sundel R. Vasculitis in childhood. Curr Opin Rheumatol. 2001;13:422-427.
20. Fukunishi M, Kikkawa M, Hamana K, et al. Prediction of non-responsiveness to intravenous high dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr. 2000;137:172-176.
21. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics. 1979;63:175-179.
22. Shulman ST. Is there a role for corticosteroids in Kawasaki disease? J pediatr. 2003;142(6):601-603.
23. Shetty AK, Homsi O, Ward K, et al. Massive lymphadenopathy and airway obstruction in a child with Kawasaki disease: success with pulse steroid therapy. J Rheumatol. 1998;25(6):1215-1217.
24. Hung JJ, Chiu CH. Pulse methylprednisolone therapy in the treatment of immune globulin-resistant Kawasaki disease: case report and review of the literature. Ann Trop Pediatr. 2004;24:89-93.
25. Sundel RP, Baker AL, Fulton DR, et al. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr. 2003;142(6):611-616.
26. Weiss JE, Eberhard BA, Chowdhury D, et al. Infliximab as a novel therapy for refractory Kawasaki disease J Rheumatol. 2004;31(4):808-810.